Key result
Catheter-directed thrombolysis represents a viable treatment option for submassive pulmonary embolism, rapidly reducing right heart strain with an acceptably low rate of major hemorrhagic complications.
Catheter-directed thrombolysis is highlighted as an evolving and viable treatment option for submassive pulmonary embolism due to its ability to rapidly reduce right heart strain with low bleeding risk.
Answers are grounded in this paper and cite their sources.
Supports CDT consideration in submassive PE; leaves open its role pending randomized trials.
Pulmonary embolism (PE) is the leading cause of in-hospital morbidity and mortality and accounts for approximately 100,000 deaths in the United States and 300,000 deaths in Europe annually. Although societal guidelines for low- and high-risk PE are well established, the present management of submassive (intermediate)-risk PE is evolving. Catheter-directed thrombolysis (CDT) represents a viable treatment option for treatment of submassive PE given its ability to rapidly reduce right heart strain with an acceptably low rate of major hemorrhagic complication. The current review aims to discuss the existing guidelines and literature supporting CDT for PE and also to examine upcoming areas of future research to support its adoption in the algorithm for the management of submassive PE.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2018) conducted a review in Pulmonary embolism. Catheter-directed thrombolysis (CDT) was evaluated. Catheter-directed thrombolysis represents a viable treatment option for submassive pulmonary embolism, rapidly reducing right heart strain with an acceptably low rate of major hemorrhagic complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: